Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Pirfenidone
Drug ID BADD_D01783
Description Pirfenidone is an orally active small molecule drug that may inhibit collagen synthesis, down regulate production of multiple cytokines and block fibroblast proliferation and stimulation in response to cytokines. Pirfenidone has demonstrated activity in multiple fibrotic conditions, including those of the lung, kidney and liver. It is being investigated by InterMune.
Indications and Usage For the treatment of idiopathic pulmonary fibrosis (IPF).
Marketing Status approved; investigational
ATC Code L04AX05
DrugBank ID DB04951
KEGG ID D01583
MeSH ID C093844
PubChem ID 40632
TTD Drug ID D02WCI
NDC Product Code 0480-3610; 60862-005; 69766-030; 76072-1006; 42385-924; 69539-120; 42385-923; 42385-925; 42571-336; 69097-940; 72205-182; 0781-8085; 0480-3611; 65372-1197; 82920-705; 16729-468; 46708-479; 69238-1640; 62332-480; 0781-2158; 62207-004; 31722-872; 50228-442; 69539-119; 57297-140; 73309-052; 46708-480; 69097-988; 69238-1641; 42571-329; 46016-5312; 31722-873; 72205-181; 76282-716; 0781-8086; 53104-7712; 69037-0013; 60219-1640; 60219-1641; 47621-311; 59285-013; 59651-199; 50228-443; 50242-121; 60219-1642; 62332-479; 46016-5310; 16729-467; 42385-926; 42571-335; 50228-441; 50242-122; 69097-987; 76282-715; 76282-717; 11014-0214; 46438-0648; 62512-0070; 50242-123
UNII D7NLD2JX7U
Synonyms pirfenidone | 5-methyl-1-phenyl-2-(1H)-pyridone | Esbriet | deupirfenidone | 1-phenyl-5-(trideuteriomethyl)-1,2-dihydropyridin-2-one | Deskar
Chemical Information
Molecular Formula C12H11NO
CAS Registry Number 53179-13-8
SMILES CC1=CN(C(=O)C=C1)C2=CC=CC=C2
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neoplasm malignant16.16.01.0010.002291%Not Available
Nephrolithiasis20.04.01.0020.001254%
Nervous system disorder17.02.10.001--Not Available
Nonspecific reaction08.01.03.0400.000530%Not Available
Ocular hypertension06.03.01.0030.000241%Not Available
Oesophageal achalasia07.02.03.0040.000241%Not Available
Oesophageal pain07.01.05.0120.000820%
Oesophageal spasm07.02.04.0040.000820%Not Available
Pancreatitis07.18.01.001--
Panic attack19.06.04.0010.001543%Not Available
Parosmia22.04.03.007; 17.04.04.0020.001230%Not Available
Personality change19.05.01.006; 17.02.05.0190.000940%
Photophobia17.17.02.006; 06.01.01.0040.001061%
Photosensitivity reaction23.03.09.0030.043569%
Pleural disorder22.05.03.0020.000241%Not Available
Pleural effusion22.05.02.002--
Pneumothorax22.05.02.0030.003617%
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.009--
Productive cough22.02.03.0050.006920%
Prurigo23.03.04.017--Not Available
Pruritus23.03.12.0010.033611%
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.006124%
Pulmonary hypertension24.08.03.002; 22.06.01.0010.003014%
Pulmonary oedema22.01.03.003; 02.05.02.0030.002411%
Pulmonary thrombosis22.06.02.003; 24.01.06.0020.000603%Not Available
Rales22.12.01.0110.000362%Not Available
Rash23.03.13.0010.110405%Not Available
Rash erythematous23.03.13.0290.003400%Not Available
Rash macular23.03.13.0030.001881%Not Available
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 12 Pages